| (Values in U.S. Thousands) | Jun, 2014 | Jun, 2013 | Jun, 2012 | Dec, 2017 | Sep, 2017 |
| Sales | 46,560 | 67,500 | 69,610 | 0 | 0 |
| Sales Growth | -31.02% | -3.03% | unch | unch | unch |
| Net Income | -640 | 6,670 | 6,360 | 0 | 0 |
| Net Income Growth | -109.60% | +4.87% | unch | unch | unch |
Tianyin Pharmaceutical CO (TPIY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
TIANYIN is a manufacturer and supplier of modernized Traditional Chinese Medicine in China. It has a comprehensive product portfolio of 33 modernized TCMs and 4 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 48 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople.
Fiscal Year End Date: 06/30